depending on the time of administration of the potential inhibitor.

The situation is even more complex if the endogenous probe is to be evaluated in patients rather than healthy volunteers. For example, plasma concentrations of \( N \)-methylnicotinamide and its metabolite 2PY (\( N \)-methyl-2-pyridone-5-carboxamide) are higher in patients with type 2 diabetes.\(^8\) Alterations in liver function must also be considered as confounders for \( N \)-methylnicotinamide plasma and urinary concentrations.\(^9\) It will be necessary to compare the impact of perpetrator drugs on the extent of changes in renal clearance of \( N \)-methylnicotinamide between different ethnic groups.

Conclusions

Endogenous probes for drug transporter function could become a valuable tool during drug development. For example, it would be very easy to determine the impact of a new molecular entity on renal clearance of an endogenous probe such as \( N \)-methylnicotinamide in phase I clinical trials. This will be particularly interesting for new molecular entities for which \emph{in vitro} studies have shown a presumably clinically relevant or borderline magnitude of drug transporter inhibition. Certainly, measurement of endogenous probes cannot replace thorough \emph{in vitro} investigations of the perpetrator drug as inhibitor of drug transport. However, if we manage to extend our understanding of how to extrapolate from drug–endogenous probe interactions to drug–drug interactions, and if we are able to avoid false-negative interpretations of the results from studies with endogenous probes such as \( N \)-methylnicotinamide, this would be a major step forward for the prediction of transporter-mediated drug–drug interactions.

ACKNOWLEDGMENTS
The author's work on the discussed topics is supported by the German Federal Ministry of Education and Research (BMBF, project grant 01EX1015B) and the DOKTOR ROBERT PFLEGER—Stiftung Bamberg.

CONFLICT OF INTEREST
The author received personal compensation for expert testimony from Boehringer Ingelheim and payments for lectures from Bayer-Schering Pharma AG and Sanofi. His institution received compensation for commissioned research of his group from Merck KGaA and compensation for supply for \emph{in vitro} studies from Gilead.

© 2012 ASCPT

1. Zhang, L., Huang, S.M. & Lesko, L.J. Transporter-mediated drug–drug interactions. \emph{Clin. Pharmacol. Ther.} \textbf{89}, 481–484 (2011).
2. Zolk, O. & Fromm, M.F. Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. \emph{Clin. Pharmacol. Ther.} \textbf{89}, 798–805 (2011).
3. Müller, F. & Fromm, M.F. Transporter-mediated drug–drug interactions. \emph{Pharmacogenomics} \textbf{12}, 1017–1037 (2011).
4. European Medicines Agency. European Medicines Agency updates guideline on drug interactions <http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/07/news_001561.jsp&mid=WCOb01ao58004dSc1> (6 July 2012).
5. US Food and Drug Administration. Guidance for Industry: Drug Interaction Studies—Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations (Draft Guidance) <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf> (14 September 2012).
6. Ito, S. \emph{et al.} \( N \)-Methylnicotinamide is an endogenous probe for evaluation of drug–drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). \emph{Clin. Pharmacol. Ther.} \textbf{92}, 635–641 (2012).
7. Shim, C.K., Sawada, Y., Iga, T. & Hanano, M. Effect of experimental acute renal failure on intrinsic renal tubular secretory clearance of organic cations in rats. \emph{J. Pharmacobiodyn.} \textbf{6}, 787–789 (1983).
8. Salek, R.M. \emph{et al.} A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. \emph{Physiol. Genomics} \textbf{29}, 99–108 (2007).
9. Pumpl, R., Sarnelli, G., Spinella, A., Budillon, G. & Cuomo, R. The metabolism of nicotinamide in human liver cirrhosis: a study on \( N \)-methylnicotinamide and 2-pyridone-5-carboxamide production. \emph{Am. J. Gastroenterol.} \textbf{96}, 1183–1187 (2001).

See ARTICLE page 631

Models of Excellence: Improving Oncology Drug Development

MR Sharma\(^1\)–\(^3\), ML Maitland\(^1\)–\(^3\) and MJ Ratain\(^1\)–\(^3\)

Simulations based on disease-progression models and phase II trial results can predict phase III results and have the potential to improve oncology drug development by informing end-of-phase II decisions (EOP2Ds). Many barriers impede effective use of modeling and simulation (M&S) for EOP2Ds in oncology: concerns about model validity, lack of access to M&S results and patient–level data, limited awareness of M&S among academic oncologists, and inexperience fitting M&S into the drug development timeline.

The statistician George E.P. Box famously wrote “essentially, all models are wrong, but some are useful.”\(^1\) He was making the point that, although models make predictions that never perfectly reflect reality, they can still be powerful tools for guiding decisions. M&S has been used to guide decision making for nononcology drugs in development, and they have the potential to do

---

\(^1\)Department of Medicine, University of Chicago, Chicago, Illinois, USA; \(^2\)Comprehensive Cancer Center, University of Chicago, Chicago, Illinois, USA; \(^3\)Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, Illinois, USA. Correspondence: MJ Ratain (mratain@medicine.bsd.uchicago.edu)

doi:10.1038/clpt.2012.99
the same for the largest active area of development: oncology drugs.

Disease-progression models are mixed-effects mathematical models that describe the relationship between a quantitative measure of disease status and time. These models support use of M&S to guide decision making in drug development. The potential of this approach was recently demonstrated in studies of Alzheimer’s disease and rheumatoid arthritis, in which models based on validated scales of symptom severity enabled efficacy comparisons to existing drugs.2,3 In both examples, M&S was used not only to support a go/no-go decision regarding further development but also to guide the optimal design of the subsequent trial, saving resources and enhancing the probability of success.

In 2009, two landmark studies introduced disease-progression models in oncology. In solid-tumor oncology, the usual measure of disease status is tumor size, conventionally defined as the sum of longest diameters of target lesions measured on routinely performed cross-sectional imaging studies. Wang (and his colleagues at the US Food and Drug Administration) used data from four registration trials in advanced non–small cell lung cancer (NSCLC) to develop drug-specific models of tumor size, as well as a drug-independent model linking overall survival (OS) to baseline prognostic factors and early change in tumor size.4 Similarly, Claret et al. used data from a phase II trial of capecitabine and a phase III trial of 5-fluorouracil–leucovorin in metastatic colorectal cancer to develop drug-specific models of tumor size, as well as a drug-independent model linking OS to baseline prognostic factors and early change in tumor size.5 These studies implied that data from phase II trials could be used to predict accurately a range of outcomes for hypothetical phase III trials and inform the design of potential phase III trials, providing valuable information for EOP2Ds.

In the article by Claret et al., in this issue of Clinical Pharmacology & Therapeutics, the authors present results of phase III trial simulations based on the aforementioned models of tumor size and overall survival in advanced NSCLC. They utilized data from a previously completed three-arm, randomized, open-label, phase II trial of carboplatin/paclitaxel (C/P) plus motesanib (an oral antiangiogenic drug, administered on either a continuous or an intermittent schedule) or bevacizumab in patients with advanced NSCLC. They simulated OS data for 700 patients receiving each of the following: C/P plus continuous motesanib (median OS 11.0 months), C/P plus intermittent motesanib (median OS 11.0 months), C/P plus bevacizumab (median OS 10.8 months), and C/P alone (median OS 9.3 months). The predicted hazard ratio (HR) for OS in hypothetical trials of C/P plus continuous motesanib vs. C/P alone was 0.87 (95% confidence interval, 0.71–1.1), with 60% of hypothetical trials having a statistically significant survival advantage for the motesanib arm (P < 0.05). The actual phase III trial of C/P plus continuous motesanib vs. C/P plus placebo (MONET1) demonstrated median OS of 13.0 vs. 11.0 months with an HR of 0.90 (95% confidence interval, 0.78–1.04; P = 0.14).

The authors conclude that the results of their simulations are “consistent with the MONET1 results.” Although this is certainly true if one uses the HR as the criteria for consistency, it is not necessarily true if one examines the OS data. The median OS for C/P plus motesanib in MONET1 (13.0 months) is greater than the upper bound of the 95% prediction interval (12.3 months) for the simulated results. Similarly, the median OS for C/P plus bevacizumab in the registration trial for bevacizumab (12.3 months) is greater than the upper bound of the 95% prediction interval (12.1 months) for the simulated results.7 Thus, the model underestimates survival in patients treated with motesanib or bevacizumab in combination with chemotherapy. Because these antiangiogenic drugs inhibit tumor growth by mechanisms different from those of cytotoxic chemotherapy, it is perhaps not surprising that the model may need to be refined to reflect more accurately their different treatment effects. As the authors point out, the disparity between observed and predicted survival might also result from known prognostic factors that are absent from the original model (e.g., histological subtype, presence of brain metastases, age) and/or differences in covariate distributions between the phase II and phase III trials.

The authors should be commended for demonstrating the potential value of M&S to support EOP2Ds in oncology. Nonetheless, there is an important detail in this example that prevented M&S from being used to its maximum potential. The authors acknowledge that the simulations were performed “while MONET1 was ongoing,” which means that the decision to move forward with phase III development was made without these results being available. MONET1 had a target accrual of 1,060 patients (530 per arm), based on having 80% power to detect an HR of 0.80 with a type I error rate of 0.03 (ref. 8). However, the simulation results demonstrate a power of only 60% with 1,400 patients (700 per arm) and a type I error rate of 0.05. In MONET1, the motesanib arm had a median OS that was two months longer than the placebo arm (13.0 vs. 11.0 months), with an HR of 0.90, but the results did not reach statistical significance, suggesting that the study was underpowered. A simulation-based power calculation before launching the phase III trial could have been used to predict the number of patients necessary to achieve 80% power, which would have substantially exceeded 1,400 patients. It is unclear whether the sponsor would have spent the resources necessary to complete the trial in these circumstances, especially in that bevacizumab was already commercially available for use in combination with C/P.

What are the barriers to more successful applications of M&S to improve oncology drug development? One barrier is the accuracy and precision of the models, although the published models are an excellent starting point for future investigation. As models are applied to novel settings and performance is continually reevaluated, opportunities to incorporate previously unrecog-
nized covariates arise and the models improve. A second barrier is the paucity of publicly available information about M&S done in the private sector. The study by Claret et al. was the result of collaboration between quantitative pharmacologists at a large pharmaceutical company and their external consultants. In the current drug development climate, divisions dedicated to “quantitative pharmacology” or “modeling and simulation” exist at most large pharmaceutical companies, and a multitude of consulting companies have sprang up to support their efforts as well as those of their smaller counterparts. Given the large number of individuals employed to conduct these sorts of analyses, the absence of more examples in the literature is striking. It is understandable that sponsors have little incentive to publish results from M&S before a potential registration application, but results should be published eventually.

A third barrier is the lack of public access to patient-level data from completed trials. To partially solve this problem, we propose the creation of a new public database for federally funded clinical trials data with submission required by National Institutes of Health policy. The goal of this database would be to create a resource for M&S, as well as for re-analysis of completed trials. A model for how to do this successfully could be the database of Genotypes and Phenotypes (dbGAP), which was established in 2007 by the National Center for Biotechnology Information to facilitate the progress of clinical applications of genetics research.

A fourth barrier is the limited awareness of M&S in the academic oncology community. Non-industry-sponsored oncology clinical trials around the world are typically government-funded and conducted through cooperative groups, with lead investigators at academic institutions. M&S could be used to prioritize proposed studies as well as to improve the efficiency of such studies. A professional campaign to increase awareness of M&S in the academic oncology community and foster collaboration between oncologists and pharmacometricians would be a good first step, but resources to support the collection and verification of quantitative data will also be required.

A final barrier is inexperience with fitting M&S into the conventional drug development timeline. EOP2Ds are typically made very quickly after phase II results become available, whereas results of M&S based on these data might take several months to become available. One potential solution to this dilemma is the increased use of combined phase II–III trials, in which an interim analysis is planned and conducted at the end of the phase II portion while accrual continues on the phase III portion. In this setting, M&S could be undertaken side by side with conventional statistical analyses and used to guide the decision about whether to continue forward with the phase III trial. These analyses could even be repeated at intervals with preliminary phase III data so as to inform changes to target accrual and possible decisions about early termination, similar to adaptive designs that are increasingly used in oncology trials.

**Figure 1** schematically illustrates this proposed paradigm.

Given the high failure rate of phase III trials in oncology and the current economic climate for funding new trials, it is more important than ever to use all tools available to optimize the efficiency and success rate of drug development. As Claret et al. show, M&S has the potential to enhance oncology drug development by informing EOP2Ds. However, M&S in oncology drug development will not fulfill its potential if we do not recognize and overcome the significant but remediable barriers to success.

**ACKNOWLEDGMENTS**

M.R.S. is the recipient of National Institutes of Health training grant T32GM007019 for Clinical Therapeutics. M.L.M. is the recipient of National Cancer Institute Mentored Career Development Award K23CA124802. M.J.R. is the recipient of a Conquer Cancer Foundation Translational Research Professorship Award.

**CONFLICT OF INTEREST**

M.R.S and M.J.R have no relevant conflicts to disclose. M.L.M has received confidential data and reimbursement for travel expenses from GlaxoSmithKline for related research.

© 2012 ASCPT

1. Box, G.E.P. & Draper, N.R. Empirical Model-Building and Response Surfaces (Wiley, New York, 1987).
2. Lockwood, P. et al. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with slow onset of effect; an example in Alzheimer’s disease. Pharm. Res. 23, 2050–2059 (2006).
3. Nixon, R.M. et al. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. Pharm. Stat. 8, 371–389 (2009).
4. Wang, Y. et al. Elucidation of relationship between tumor size and survival in non–small-cell lung cancer patients can aid early decision making in clinical drug development. Clin. Pharmacol. Ther. 86, 167–174 (2009).
5. Claret, L. et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J. Clin. Oncol. 27, 4103–4108 (2009).
6. Claret, L. et al. Simulations using a drug–disease modeling framework and phase II data predict phase III survival outcome in first-line non–small-cell lung cancer. Clin. Pharmacol. Ther. 92, 631–634 (2012).
7. Sandler, A. et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N. Engl. J. Med. 355, 2542–2550 (2006).
8. Scaglotti, G. et al. An international, randomized, placebo-controlled, double-blind phase III study (MONEIT) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non–small cell lung cancer (NSCLC) (abstract) J. Clin. Oncol. 29 (suppl) LB7512 (2011).
9. Mailman, M.D. et al. The NCBI dbGaP database of genotypes and phenotypes. Nat. Genet. 39, 1181–1186 (2007).
10. Berry, D.A. Adaptive clinical trials in oncology. Nat. Rev. Clin. Oncol. 9, 199–207 (2011).